Advancements in assay & analytic development in the vaccines field

Vaccine Insights 2022; 1(5), 259–265

DOI: 10.18609/vac.2022.037

Published: 8 November 2022
Jessica White

Charlotte Barker, Editor, BioInsights, speaks to Jessica White, Vaccine Formulations Team, PATH, about her career in immunology and infectious disease, and her recent work on in vitro inhibition ELISA assays

Jessica White is a virologist who has been working at PATH for the past 10 years on the Vaccine and Pharmaceutical formulation technologies and the Chemistry and Manufacturing Controls teams. She has a PhD in Comparative Pathology from University of California, Davis and completed two postdoctoral positions at University of Washington as a research fellow in Infectious Diseases and Immunology and one at PATH in vaccine formulation. Jessica supports the development of vaccine candidates for Shigella, E. coli, Rotavirus, Measles and Rubella, Novel Oral Polio Virus, Non-Salmonella Typhoid, and SARS CoV-2. To improve global access to these critical immunizations, her team specializes in producing novel thermostable and needle-free vaccine formats, such as fast dissolving tablets. Currently, Jessica is leading the work to produce and characterize monoclonal antibodies specific against the SARS CoV-2 variants for use by vaccine manufacturers and researchers.